As amyloid falls out of favor, here’s where Alzheimer’s R&D is headed next
The Alzheimer’s pipeline is growing as drug developers put more emphasis on inflammation, tau and biomarkers.
The Alzheimer’s pipeline is growing as drug developers put more emphasis on inflammation, tau and biomarkers.